Influenza A H3N2
6
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (6)
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)
Study Examining PrEP-001 in Healthy Subjects
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults